AASLD MASLD Beverage Guidance 2025 Raises Eyebrows
- 01. Primary AASLD MASLD beverage guidance for 2025
- 02. What AASLD actually says about MASLD and drinks
- 03. Specific beverage cautions in 2025 guidance
- 04. Why "diet" drinks are now under the spotlight
- 05. Alcohol and MASLD in the 2025-2030 context
- 06. Practical beverage-switching strategies for MASLD
Primary AASLD MASLD beverage guidance for 2025
In 2025, the American Association for the Study of Liver Diseases (AASLD) updated its practice guidance on metabolic dysfunction-associated steatotic liver disease (MASLD) and intensified its stance on beverage choices, explicitly cautioning against both sugar-sweetened beverages and artificially sweetened drinks. The core message is that routine consumption of soft drinks, even "diet" variants, is associated with a higher risk of MASLD and should be minimized; the safest everyday beverage for most people with or at risk for MASLD is plain water.
What AASLD actually says about MASLD and drinks
AASLD's 2025-2026 updates to the MASLD practice guidance continue to frame liver-oriented nutrition around calorie control, macronutrient quality, and avoidance of metabolic "stressors," including high-fructose additives and alcohol. While the guidance does not prescribe a rigid "beverage menu," it explicitly flags sugar-sweetened beverages-such as regular soda, sweetened iced tea, and sports drinks-as contributors to excess calorie intake, hepatic fat deposition, and insulin resistance, all of which worsen MASLD progression.
Separately, large cohort studies published in 2025 have reshaped how liver experts view artificially sweetened drinks. Analyses of over 120,000 participants in the UK Biobank found that consuming more than about 250 g (roughly one can) per day of either sugar-sweetened beverages (SSBs) or low- or no-sugar-sweetened beverages (LNSSBs, i.e., diet drinks) raised the hazard ratio for developing MASLD by 50% and 60%, respectively. In practical terms, even "diet" soda appears to elevate MASLD risk, challenging the long-standing assumption that it is a neutral substitute.
Specific beverage cautions in 2025 guidance
On the basis of this evidence, AASLD and allied hepatology bodies now warn that the following drink categories should be limited or avoided in patients with or at risk for MASLD:
- Sugar-sweetened sodas (cola, citrus-flavored sodas, fruit-flavored sodas) at any regular intake frequency.
- Energy drinks and high-sugar sports drinks, which deliver concentrated fructose and glucose loads.
- Pre-sweetened teas and coffees, including many bottled "iced tea" products and ready-to-drink mochas.
- Artificially sweetened colas and flavored diet drinks under the rationale that they are linked to metabolic dysregulation and may increase MASLD risk per study data.
- Regular alcohol consumption, especially in the setting of MASLD or advanced fibrosis, where any alcohol intake is seen as additive risk rather than neutral.
| Beverage type | Typical daily intake (2025 context) | Approx. relative risk for MASLD* | AASLD-aligned 2025 stance |
|---|---|---|---|
| Plain water | 1.5-2 L | Reference (1.0) | Recommended as primary beverage. |
| Unsweetened herbal or black tea | 2-3 cups | 0.9-1.1 | Generally acceptable; prefer over sweet drinks. |
| Black coffee without sugar | 1-2 cups | 0.8-1.0 | Neutral; may have modest benefits in observational data. |
| Sugar-sweetened soda (regular cola) | 330-500 mL (1 can) | ~1.5 (≈50% higher) | Discourage; limit to rare occasions or zero. |
| Diet soda (artificially sweetened) | 250-500 mL (1 can) | ~1.6 (≈60% higher) | Warn against regular use; no safe "daily" threshold. |
| Energy drinks or high-sugar sports drinks | 250-500 mL | ~1.7-1.9 | Strongly discourage; especially in adolescents and young adults. |
| Non-daily, low-volume alcohol (e.g., 1 drink/week) | ≤14 g ethanol | ~1.1-1.3 | Controversial; many experts advise absolute avoidance in MASLD with fibrosis. |
*Relative risk figures are approximated from 2025 UK cohort data associating beverage intake with incident MASLD; AASLD does not publish formal numeric thresholds but endorses the underlying risk gradient.
Why "diet" drinks are now under the spotlight
For years, artificially sweetened beverages were marketed as metabolically safer alternatives to sugar-sweetened drinks, but 2025 data are shifting that narrative. The UK Biobank study reported that individuals consuming more than 250 g per day of low- or no-sugar-sweetened beverages had a 60% higher risk of developing MASLD (hazard ratio 1.599), compared with non-drinkers, even after adjusting for body mass index and other cardiometabolic risk factors.
Experts hypothesize that artificial sweeteners may disrupt gut microbiota, alter insulin signaling, and condition intense sugar cravings, collectively promoting the same metabolic milieu that underlies MASLD. One co-author of the 2025 study stated, "Our study shows that LNSSBs were actually linked to a higher risk of MASLD, even at modest intake levels such as a single can per day," underscoring that low-calorie does not equate to liver-safe. In practice, 2025 guidance increasingly urges clinicians to treat diet soda and regular soda as similarly problematic in the context of hepatic metabolism.
Alcohol and MASLD in the 2025-2030 context
Concurrent with the 2025 MASLD beverage focus, AASLD has also voiced concern about the 2025-2030 Dietary Guidelines for Americans (DGA), which removed specific daily limits for alcohol and instead offer only a vague "consume less alcohol" directive. AASLD's statement, issued on January 7, 2026, argues that people deserve clear, evidence-based thresholds, particularly for those with metabolic risk factors or existing liver disease.
Existing MASLD/MASH literature consistently notes that alcohol consumption, even at "moderate" levels, increases the risk of cirrhosis and hepatocellular carcinoma in patients with metabolic liver disease. For that reason, many hepatologists now recommend that patients with MASLD and significant fibrosis (stage F2 or higher by non-invasive tests) avoid alcohol entirely, rather than relying on soft DGA phrasing. This stricter stance has become part of the de-facto 2025 clinical ethos underlying AASLD-aligned lifestyle counseling.
Practical beverage-switching strategies for MASLD
Substitution rather than simple restriction is a key theme in 2025 AASLD-aligned messaging. Research from the 2025 UK cohort showed that replacing sugar-sweetened beverages with water reduced MASLD risk by 12.8%, while replacing diet drinks with water cut risk by 15.2%. In contrast, switching from regular soda to diet soda did not significantly lower MASLD risk, suggesting that the "sugar-free" label alone does not confer liver-protective benefit.
- Step 1: Identify current sugar-sweetened beverage intake (e.g., 2 cans of soda daily) and quantify added sugar grams per day.
- Step 2: Replace one serving at a time with unsweetened options such as plain water, sparkling water, or unsweetened herbal tea over 2-4 weeks.
- Step 3: Gradually phase out artificially sweetened drinks by offering small-volume alternatives (e.g., 125 mL sparkling water with a slice of lemon) and retraining taste preferences.
- Step 4: For patients with MASLD, conduct a formal alcohol review and, in the presence of fibrosis, recommend abstinence rather than "moderation."
- Step 5: Re-evaluate liver enzymes and metabolic risk markers after 6-12 months of consistent beverage changes as part of routine MASLD monitoring.
Helpful tips and tricks for Aasld Masld Beverage Guidance 2025 Raises Eyebrows
What the AASLD beverage table shows for 2025?
The table below summarizes the 2025 AASLD-aligned stance on common beverages for people with or at risk for MASLD, using realistic risk categories and example data drawn from recent MASLD epidemiology and beverage-exposure studies. These relative risk figures are illustrative rather than official AASLD thresholds, but they reflect the magnitude of effect seen in population-level analyses.
Is any level of soda safe for MASLD?
The 2025 evidence does not define a clearly "safe" daily threshold for sugar-sweetened beverages in MASLD, but it does show a graded risk increase starting at modest intake levels. For example, a single can of soda per day was associated with roughly a 50% higher risk of MASLD in the UK cohort, while higher volumes (two or more cans) pushed the hazard ratio even higher. In light of this, most AASLD-aligned clinicians now advise that patients with MASLD either avoid regular soda entirely or limit it to rare, symbolic occasions rather than routine consumption.
Are diet drinks completely forbidden?
Artificially sweetened beverages are not formally "forbidden" in any single AASLD guideline document, but emerging epidemiology has pushed experts toward a strong cautionary stance. The 2025 UK analysis tied daily consumption of diet drinks equivalent to about one can to a 60% higher MASLD risk, with no clear plateau of safety at low volumes. As a result, 2025 clinical guidance increasingly frames diet soda as a beverage to be minimized or phased out entirely, with water presented as the preferred default.
What if someone has both MASLD and diabetes?
For patients with both MASLD and type 2 diabetes, beverage choices matter doubly because of the interplay between hepatic fat, insulin resistance, and cardiovascular risk. Observational and clinical trial data suggest that eliminating or sharply reducing sugar-sweetened beverages can improve glycemic control and reduce hepatic steatosis over time. In this subgroup, artificial sweeteners remain controversial; some endocrinologists and hepatologists argue that non-nutritive sweeteners may perpetuate sugar cravings and metabolic dysregulation, so the safest approach is to rely on water, unsweetened tea, and occasionally unsweetened coffee.
What do gastroenterologists actually tell patients now?
Front-line gastroenterologists and hepatologists are increasingly aligning their counseling with the 2025 cohort data. A typical 2025 clinic script might be: "We now have strong evidence that even one sugary or diet drink per day can raise your risk of MASLD, so the safest strategy is to switch to water as your main drink and reserve soda for very rare occasions." This messaging is reinforced during MASLD screening visits, where clinicians pair beverage advice with brief discussions of weight management, physical activity, and tighter control of cardiometabolic risk factors.
What future research is likely to change the guidance?
Ongoing large-scale studies tracking beverage patterns and liver outcomes will likely refine the 2025-2026 guidance over the next several years. Current knowledge gaps include whether specific artificial sweeteners (e.g., aspartame versus sucralose) carry different hepatic risks, and whether targeted interventions (e.g., structured beverage-substitution programs) can measurably reduce MASLD incidence and progression. As more randomized data emerge, AASLD may move toward more explicit, numeric limits or even category-specific "red, amber, green" beverage labels for MASLD-prone populations.
How can primary-care providers apply this guidance tomorrow?
Primary-care clinicians can operationalize the 2025 AASLD MASLD beverage guidance by integrating a focused beverage screen into routine visits for patients with obesity, diabetes, or abnormal liver enzymes. A simple workflow might include asking about daily soda, sports drinks, and diet soda intake; briefly explaining the 50-60% risk gradients seen in 2025 data; and offering a written tip sheet that lists concrete swaps (e.g., "Replace 1 can of regular soda with 500 mL water or sparkling water"). Over time, these modest changes can substantially reduce the cumulative metabolic burden on the liver and complement emerging pharmacologic therapies such as semaglutide for MASH-with-fibrosis.